News

  • The importance of clinical pharmacology and exposure response in oncology drug development

    Last week in The ASCO Post (Harborside Press), a discussion of the importance of clinical pharmacology and exposure response in oncology drug development was published.

    Julie Bullock
  • A review of key 2014 publications and conference abstracts from d3 Medicine

    d3 Medicine contributed to more than 11 significant peer reviewed publications and 15 conference abstracts during 2014.

    Patrick Smith
  • d3 Medicine welcomes a new Director - Dr. Julie Bullock PharmD from the FDA

    Dr. Bullock has over 10 years of drug development experience within the FDA. Dr Bullock's past appointments include Clinical Pharmacology Team Leader and Senior Clinical Pharmacology Reviewer. Her regulatory experience was focused in the therapeutic areas of hematology/oncology and coagulation.

    d3
  • d3 Medicine congratulates Alios Biopharma on the Announcement of a $1.75Bn Acquisition Agreement with Johnson & Johnson

    On September 30, 2014 Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, announced a definitive agreement with Johnson & Johnson whereby Alios will be acquired for approximately $1.75 billion in cash payable upon closing of the transaction.

    Patrick Smith
  • Australian Government Supports MCPA

    Assistant Minister for Defence Stuart Robert was briefed by the Steering Committee of Medical Countermeasures Products Australia (MCPA), an industry-led initiative that aims to develop national capability and support the activities undertaken by the Departments of Defence and Health as part of the Medical Countermeasures Consortium.

    Leigh Farrell
  • d3 Medicine LLC and Viroclinics Biosciences BV form virology drug development alliance to serve the biopharmaceutical industry

    d3 Medicine, and Viroclinics Biosciences, announced today that they have signed a non-exclusive Memorandum of Understanding to provide biopharmaceutical customers with an integrated solution to accelerate the preclinical and clinical development of drugs, biologicals, vaccines and diagnostics.

    d3
  • Sydney Morning Herald: Funding under the microscope

    We are very encouraged by the Australian government’s commitment to a 20 billion dollar Medical Research Future Fund.  In the event it is afforded safe passage by the Senate, we sincerely hope that some of the investment is used to enhance specialist drug development skills for Australia.

    d3
  • New publication supporting FDA expansion of Tamiflu’s use to treat children under 1 year

    Today in Clinical Pharmacology and Therapeutics (Nature Publishing Group), the clinical pharmacology strategy and methods were published supporting FDA’s approval of Tamiflu for babies less than one year of age.

    Craig Rayner
  • Wall Street Journal: Arch Biopartners Hires d3 Medicine to Develop a Human Trial for Brain Tumor Targeting Technology

    Arch Biopartners announced today it has hired d3 Medicine to work as the Company's new drug development team.

    Patrick Smith
  • d3 Medicine is looking for talent - two vacancies in our New Jersey office

    (i) Director of Clinical Pharmacology/Translational Medicine

    (ii) Operations Manager

    Click here for more information.

    d3
  • UN Symposium: An Integrated Future - Multisectoral Partnerships and Perspectives in Global Health

    d3 Medicine supported the organization of a Special Side Event on the Role of Partnerships in the Implementation of the Post 2015 Development Agenda as part of a Joint Event of the United Nations General Assembly and the Economic and Social Council (ECOSOC) entitled “The role of partnerships in t

    Craig Rayner
  • d3 Medicine US office opens in Parsippany, New Jersey

    Located just 20mins from Newark airport, Parsippany NJ is known for its concentration of biotech/pharma companies including Daiichi Sankyo, The Medicines Company, GSK, and Novartis and many more.

    d3
  • Strategies to reduce hematologic toxicity of linezolid whilst maintaining efficacy

    Thrombocytopenia is a common side effect of linezolid, an oxazolidinone antibiotic often used to treat multidrug-resistant Gram-positive bacterial infections. d3 medicine contributed to a clinical investigation recently published in Antimicrobial Agents and Chemotherapy.

    Patrick Smith
  • Establishment of Medical Countermeasures Products Australia (MCPA)

    The inaugural meeting of Medical Countermeasures Products Australia (MCPA) was convened. MCPA represents a national taskforce of medical, industry, academic and government stakeholders, who are committed to advancing Australia’s interests in medical countermeasures preparedness.

    Leigh Farrell
  • A review of key 2013 publications from d3 Medicine

    d3 medicine contributed to more than a dozen significant peer reviewed publications during 2013.

    Regina Dutkowski

Pages